JP2019507180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507180A5 JP2019507180A5 JP2018546596A JP2018546596A JP2019507180A5 JP 2019507180 A5 JP2019507180 A5 JP 2019507180A5 JP 2018546596 A JP2018546596 A JP 2018546596A JP 2018546596 A JP2018546596 A JP 2018546596A JP 2019507180 A5 JP2019507180 A5 JP 2019507180A5
- Authority
- JP
- Japan
- Prior art keywords
- adjuvant
- seq
- composition
- optionally
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022027569A JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
| JP2024000506A JP7785817B2 (ja) | 2016-03-04 | 2024-01-05 | がんに対する組合せ療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603805.1A GB201603805D0 (en) | 2016-03-04 | 2016-03-04 | Combination |
| GB1603805.1 | 2016-03-04 | ||
| GB1610018.2 | 2016-06-08 | ||
| GBGB1610018.2A GB201610018D0 (en) | 2016-06-08 | 2016-06-08 | Combination |
| PCT/EP2017/055093 WO2017149150A1 (en) | 2016-03-04 | 2017-03-03 | Combination therapy against cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022027569A Division JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019507180A JP2019507180A (ja) | 2019-03-14 |
| JP2019507180A5 true JP2019507180A5 (enExample) | 2020-04-09 |
Family
ID=58231605
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546596A Pending JP2019507180A (ja) | 2016-03-04 | 2017-03-03 | がんに対する組合せ療法 |
| JP2022027569A Active JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022027569A Active JP7417645B2 (ja) | 2016-03-04 | 2022-02-25 | がんに対する組合せ療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190343940A1 (enExample) |
| EP (2) | EP3423087B1 (enExample) |
| JP (2) | JP2019507180A (enExample) |
| DK (1) | DK3423087T3 (enExample) |
| ES (1) | ES2965009T3 (enExample) |
| FI (1) | FI3423087T3 (enExample) |
| HR (1) | HRP20240052T1 (enExample) |
| HU (1) | HUE064857T2 (enExample) |
| LT (1) | LT3423087T (enExample) |
| PL (1) | PL3423087T3 (enExample) |
| PT (1) | PT3423087T (enExample) |
| SI (1) | SI3423087T1 (enExample) |
| WO (1) | WO2017149150A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| IL307242A (en) | 2016-12-07 | 2023-11-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| ES2899616T3 (es) | 2017-04-28 | 2022-03-14 | Five Prime Therapeutics Inc | Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central |
| PE20200797A1 (es) | 2017-08-25 | 2020-08-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen especificamente a b7-h4 humana |
| WO2019102265A1 (en) | 2017-11-23 | 2019-05-31 | Theraphage Inc. | Peptide displaying bacteriophage nanoparticles and related compositions and methods |
| JP2021504336A (ja) * | 2017-11-24 | 2021-02-15 | アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ | 抗体依存性細胞媒介性細胞傷害（ａｄｃｃ）の強化 |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| GB201818576D0 (en) * | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| KR102653960B1 (ko) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | 암 치료를 위한 면역체크포인트 억제제의 병용 요법 |
| US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| GB202103673D0 (en) * | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4340948A4 (en) * | 2021-05-17 | 2025-03-12 | Wisconsin Alumni Research Foundation (WARF) | SYNTHETIC PROTEIN TO INDUCE IMMUNE TOLERANCE |
| US20250213664A1 (en) * | 2022-02-18 | 2025-07-03 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| US9433666B2 (en) * | 2008-04-17 | 2016-09-06 | IO Bioech ApS | Indoleamine 2,3-dioxygenase based immunotherapy |
| CA2850245C (en) * | 2011-10-17 | 2020-04-28 | Herlev Hospital | Pd-l1 based immunotherapy |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| MX390904B (es) * | 2014-02-04 | 2025-03-21 | Incyte Corp | Combinación de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cáncer. |
| EP3149481B1 (en) * | 2014-05-30 | 2019-01-09 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
-
2017
- 2017-03-03 SI SI201731444T patent/SI3423087T1/sl unknown
- 2017-03-03 FI FIEP17709038.8T patent/FI3423087T3/fi active
- 2017-03-03 HU HUE17709038A patent/HUE064857T2/hu unknown
- 2017-03-03 EP EP17709038.8A patent/EP3423087B1/en active Active
- 2017-03-03 PT PT177090388T patent/PT3423087T/pt unknown
- 2017-03-03 EP EP23202447.1A patent/EP4316517A3/en active Pending
- 2017-03-03 JP JP2018546596A patent/JP2019507180A/ja active Pending
- 2017-03-03 US US16/081,778 patent/US20190343940A1/en not_active Abandoned
- 2017-03-03 LT LTEPPCT/EP2017/055093T patent/LT3423087T/lt unknown
- 2017-03-03 ES ES17709038T patent/ES2965009T3/es active Active
- 2017-03-03 WO PCT/EP2017/055093 patent/WO2017149150A1/en not_active Ceased
- 2017-03-03 DK DK17709038.8T patent/DK3423087T3/da active
- 2017-03-03 PL PL17709038.8T patent/PL3423087T3/pl unknown
- 2017-03-03 HR HRP20240052TT patent/HRP20240052T1/hr unknown
-
2021
- 2021-09-07 US US17/468,263 patent/US20220257741A1/en active Pending
-
2022
- 2022-02-25 JP JP2022027569A patent/JP7417645B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507180A5 (enExample) | ||
| JP2019508444A5 (enExample) | ||
| JP2016531907A5 (enExample) | ||
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2018501197A5 (enExample) | ||
| FI3429618T3 (fi) | Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön | |
| JP2018510132A5 (enExample) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| IL277188B2 (en) | Intracellular delivery of biomolecules to modify the immune response | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| RU2016107426A (ru) | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета | |
| HRP20230512T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma jajnika i drugih karcinoma | |
| JP2018509163A5 (enExample) | ||
| JP2020512973A5 (enExample) | ||
| Ahmad et al. | PD-L1-specific T cells | |
| JP7267014B2 (ja) | 癌ワクチンにおける使用のためのｐｄｌ１ペプチド | |
| AU2021341521A1 (en) | Heterologous prime boost vaccine | |
| JP2019516768A5 (enExample) | ||
| JP2019505210A5 (enExample) | ||
| RU2020110148A (ru) | Противораковые вакцины | |
| CN117500830A (zh) | 治疗中针对cd40和cd137的多特异性结合剂 | |
| WO2015086354A3 (en) | Novel promiscuous hpv16-derived t helper epitopes for immunotherapy | |
| JP2020150950A (ja) | 抗腫瘍剤及びその評価方法 | |
| HRP20211754T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |